M344

Uses

Histone deacetylase inhibitor III. A cell-permeable amide analog of Trichostatin A that potently inhibits HDACs.

Uses

M 344 is an inhibitor of histone deacetylases (HDACs), inhibiting maize HDAC (IC50 = 100 nM) as well as human HDAC1 (IC50 = 46 nM). It shows a three-fold selectivity for inhibition of HDAC6 over HDAC1. M 344 enhances the sensitivity of human squamous carcinoma cells to radiation and promotes cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells (ED50 = 2.3 μM).

Definition

ChEBI: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide is a benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines. It has a role as an apoptosis inducer, an antineoplastic agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a member of benzamides, a hydroxamic acid, a secondary carboxamide and a tertiary amino compound.

General Description

A cell-permeable amide analog of Trichostatin A (Cat. No. 647925) that potently inhibits histone deacetylases (IC₅₀ = 40 nM for rat liver HDAC and IC₅₀ = 100 nM for maize HD). Induces differentiation and inhibits proliferation (~2 μM) of murine erythroleukemia cells.

Biological Activity

Histone deacetylase inhibitor (IC 50 = 100 nM). Induces terminal cell differentiation and causes an increase in hyperacetylated histone H4. Antiproliferative agent; suppresses the growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and apoptosis.

Biochem/physiol Actions

Cell permeable: yes

References

[1]. jung m, brosch g , kolle d, et al. amide analogues of trichostatin a as inhibitors of histone deacetylase and inducers of terminal cell differentiation. journal of medicinal chemistry, 1999, 42 (22): 4669-4679.
[2]. yeung a, bhargava rk, ahn, r, et al. hdac inhibitor m344 suppresses mcf-7 breast cancer cell proliferation. biomedicine & pharmacotherapy, 2012, 66 (3): 232-236.
[3]. furchert se, lanvers-kaminsky c , jurgens h , et al. inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. international journal of cancer, 2007, 120 (8): 1787-1794.
[4]. ying h, zhang yh , zhou x , et al. selective histonedeacetylase inhibitor m344 intervenes in hiv-1 latency through increasing histone acetylation and activation of nf-kappab. plos one, 2012, 7 (11): e48832.